Evidence map›Paper›PMID 41806022›Full record

SynthesisCurrent diabetes reports2026

Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD.

Larissa Araújo de Lucena, Deivyd V S Cavalcante, Marcela V Montenegro, Larissa C Hespanhol, William S de Oliveira, Juliana Q Muniz, Sruti Prathivadhi-Bhayankaram, Edgardo Kaplinsky, Alejandro Barbagelata, Juliana Giorgi

Erratum issuedAbstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Current diabetes reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Larissa Araújo de LucenaFederal University of Rio Grande do Norte, Natal, RN, Brazil.ORCID http://orcid.org/0000-0002-6482-5920
Deivyd V S CavalcanteUniversity of North Texas Health Science Center, Fort Worth, TX, USA.
Marcela V MontenegroUniversity of Pernambuco, Recife, PE, Brazil.
Larissa C HespanholFederal University of Campina Grande, Cajazeiras, PB, Brazil.
William S de OliveiraFederal University of Rio Grande do Norte, Natal, RN, Brazil.
Juliana Q MunizSchmieder Klinik Heidelberg, Heidelberg, Germany.
Sruti Prathivadhi-BhayankaramUniversity of Illinois, Chicago, IL, USA.
Edgardo KaplinskyHospital Municipal de Badalona, Barcelona, Spain.
Alejandro BarbagelataUniversidad Catolica Argentina, Buenos Aires, Argentina.
Juliana GiorgiSírio-Libanês Hospital, São Paulo, SP, Brazil. julianagiorgi@hotmail.com.ORCID http://orcid.org/0009-0007-7271-4845

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewPeripheral artery disease (PAD) is a serious complication in type 2 diabetes, increasing vascular morbidity and mortality. While glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists show cardiovascular benefits in diabetes, their effects on PAD-related outcomes are unclear. This meta-analysis assessed the impact of these therapies on vascular outcomes in type 2 diabetes with PAD. RECENT

findingsA systematic review and meta-analysis were conducted per PRISMA guidelines (PROSPERO CRD420251083622). PubMed, Embase, and Cochrane Central were searched. A random-effects model pooled data. Primary outcomes were major adverse limb events, peripheral revascularization, and amputation. Secondary outcomes included major adverse cardiovascular events (MACE), all-cause mortality, myocardial infarction, stroke, HbA1c, and weight changes. Six studies (four RCTs, two propensity score-matched cohorts) with 25,866 patients were included. Incretin-based therapies significantly reduced all-cause mortality (RR 0.52 [0.28–0.95], p = 0.032) and HbA1c (MD − 0.73% [–1.32 to − 0.15], p = 0.013) compared to placebo or standard care. No significant differences were found for major adverse limb events, revascularization, amputation, MACE, myocardial infarction, or stroke. Heterogeneity and low evidence certainty were noted.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide 1Hypoglycemic AgentsIncretinsPeripheral Arterial DiseaseGlucagon-Like Peptide-1 Receptor AgonistsHumansTreatment OutcomeGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsDiabetes MellitusGlucagon-Like Peptide 1Glucose-Dependent Insulinotropic PolypeptidePeripheral Arterial Disease

Identifiers

PMID41806022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.